Margherita Bigossi

Ms. Margherita Bigossi

Università Cattolica del Sacro Cuore
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SHSam Hodgson
Sam Hodgson
AWAlice Williamson
Alice Williamson
MBMargherita Bigossi
Margherita Bigossi
DSDaniel Stow
Daniel Stow
BJBenjamin M. Jacobs
Benjamin M. Jacobs
SFSarah Finer
Sarah Finer
South Asians develop type 2 diabetes (T2D) early in life and often with normal body mass index (BMI). However, reasons for this are poorly understood because genetic research is largely focused on European ancestry groups. We used recently derived multi-ancestry partitioned polygenic scores (pPSs) to elucidate underlying etiological pathways British Pakistani and British Bangladeshi individuals with T2D (n = 11,678) and gestational diabetes mellitus (GDM) (n = 1,965) in the Genes & Health study (n = 50,556). Beta cell 2 (insulin deficiency) and Lipodystrophy 1 (unfavorable fat distribution) pPSs were most strongly associated with T2D, GDM and younger age at T2D diagnosis. Individuals at high genetic risk of both insulin deficiency and lipodystrophy were diagnosed with T2D 8.2 years earlier with BMI 3 kg m− 2 lower compared to those at low genetic risk. The insulin deficiency pPS was associated with poorer HbA1c response to SGLT2 inhibitors. Insulin deficiency and lipodystrophy pPSs were associated with faster progression to insulin dependence and microvascular complications. South Asians had a greater genetic burden from both of these pPSs than white Europeans in the UK Biobank. In conclusion, genetic predisposition to insulin deficiency and lipodystrophy in British Pakistani and British Bangladeshi individuals is associated with earlier onset of T2D, faster progression to complications, insulin dependence and poorer response to medication.

Verified
Journal Article
Open access
PDF file
IGIgor Giarretta
Igor Giarretta
Eleonora GaetaniEleonora Gaetani
Eleonora Gaetani
MBMargherita Bigossi
Margherita Bigossi
PTPaolo Tondi
Paolo Tondi
TATakayuki Asahara
Takayuki Asahara
Roberto PolaRoberto Pola
Roberto Pola
Hedgehog (Hh) proteins are prototypical morphogens known to regulate epithelial/mesenchymal interactions during embryonic development. In addition to its pivotal role in embryogenesis, the Hh signaling pathway may be recapitulated in post-natal life in a number of physiological and pathological conditions, including ischemia. This review highlights the involvement of Hh signaling in ischemic tissue regeneration and angiogenesis, with particular attention to the heart, the brain, and the skeletal muscle. Updated information on the potential role of the Hh pathway as a therapeutic target in the ischemic condition is also presented.

30 May 2023 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Open access
PDF file
MBMargherita Bigossi
Margherita Bigossi
CMCyrielle Maroteau
Cyrielle Maroteau
ADAdem Y Dawed
Adem Y Dawed
ATAlasdair Taylor
Alasdair Taylor
SSSundararajan Srinivasan
Sundararajan Srinivasan
MSMoneeza K Siddiqui
Moneeza K Siddiqui
The efficacy of statin therapy is hindered by intolerance to the therapy, leading to discontinuation. Variants in SLCO1B1, which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentrations of the drug and its metabolites. Current pharmacogenetic guidelines require sequencing of the SLCO1B1 gene, which is more expensive and less accessible than genotyping. In this study, we aimed to develop an easy, clinically implementable functional gene risk score (GRS) of common variants in SLCO1B1 to identify patients at risk of statin intolerance. A GRS was developed from four common variants in SLCO1B1. In statin users from Tayside, Scotland, UK, those with a high-risk GRS had increased odds across three phenotypes of statin intolerance [general statin intolerance (GSI): ORGSI 2.42; 95% confidence interval (CI): 1.29–4.31, P = 0.003; statin-related myopathy: ORSRM 2.51; 95% CI: 1.28–4.53, P = 0.004; statin-related suspected rhabdomyolysis: ORSRSR 2.85; 95% CI: 1.03–6.65, P = 0.02]. In contrast, using the Val174Ala genotype alone or the recommended OATP1B1 functional phenotypes produced weaker and less reliable results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (ORVal174Ala 1.99; 95% CI: 1.01–3.95, P = 0.048; ORGRS 1.76; 95% CI: 1.16–2.69, P = 0.008). For those requiring high-dose statin therapy, the high-risk GRS was more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared with Val174Ala (GSI: HRVal174Ala 2.49; 95% CI: 1.09–5.68, P = 0.03; HRGRS 2.44; 95% CI: 1.46–4.08, P < 0.001). Finally, sequence kernel association testing confirmed that rare variants in SLCO1B1 are associated with the risk of intolerance (P = 0.02). We provide evidence that a GRS based on four common SLCO1B1 variants provides an easily implemented genetic tool that is more reliable than the current recommended practice in estimating the risk and predicting early-onset statin intolerance. Schematic representation of the definition of cases and controls, common SLCO1B1 variants included in the gene risk score (GRS), and findings from the study. The GRS, based on four common SLCO1B1 variants, is more reliable than Val174Ala alone in estimating the risk and predicting early onset statin intolerance.

24 September 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
MSMoneeza K. Siddiqui
Moneeza K. Siddiqui
TDTheo Dupuis
Theo Dupuis
RARanjit Mohan Anjana
Ranjit Mohan Anjana
ADAdem Y. Dawed
Adem Y. Dawed
MBMargherita Bigossi
Margherita Bigossi
AVAna Viñuela
Ana Viñuela
Background: Individuals of South and East Asian ancestry have a higher risk of type 2 diabetes, often driven by insulin deficiency due to impaired beta-cell function. The transcription factor XBP1 supports beta-cell survival by reducing cellular stress, but its role in diabetes risk and glucose regulation remains unclear. This study aimed to evaluate the impact of XBP1 expression on diabetes risk, beta-cell function, glycaemic traits, and treatment response across ancestries. Methods: We performed colocalisation analyses to test whether XBP1 expression in pancreatic islets and type 2 diabetes share causal variants. A lead variant regulating XBP1 expression was identified and analysed in two South Asian cohorts from India to assess associations with beta-cell function and glucose levels. We further assessed glycaemic control using HbA1c in cohorts of British South Asians and white Europeans. We examined the effect of the variant on drugs designed to improve insulin secretion. Results: XBP1 expression colocalises with diabetes risk in East Asians but not in white Europeans, and lower expression is associated with higher risk of diabetes. The lead SNP of the eQTL (rs7287124) is more common in East (65%) and South Asians (50%) compared to white Europeans (25%). rs7287124 is associated with lower beta-cell function using HOMA-B (P = 5 × 10−3, n = 470). In trans-ancestry meta-analyses rs7287124 is associated with 4.32 mmol/mol (95% CI: 2.60–6.04, P = 8 × 10−7) higher HbA1c. In individuals with young, non-obese onset diabetes, the trans-ancestry effect is 6.41 mmol/mol (P = 2 × 10−4). Variant carriers show impaired response to sulphonylureas. Conclusions: XBP1 expression is associated with diabetes risk with particular value in under-represented populations at risk of young, non-obese onset diabetes.

26 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SHSam Hodgson
Sam Hodgson
VBVi Bui
Vi Bui
SHSiqi Hu
Siqi Hu
CMCyrielle Maroteau
Cyrielle Maroteau
MBMargherita Bigossi
Margherita Bigossi
MSMoneeza K Siddiqui
Moneeza K Siddiqui
/ Introductory Paragraph: Type 2 diabetes (T2D) is a common and complex metabolic condition with significant heterogeneity within and across ancestries 1–4 . Compared with individuals of European ancestry (EUR), people of south Asian ancestry (SAS) have two to four-fold higher risk of T2D, develop the disease at younger ages and lower body mass index (BMI), and experience more rapid progression to complications 5–10 . Understanding the genetic basis of this is hindered by low representation of south Asians in genetic studies. Here, we perform an exome-wide association study of T2D in 13,674 cases and 41,024 controls from the Genes & Health study of British Pakistani and Bangladeshi individuals. We identify a novel rare variant in HNF4A – a canonical monogenic diabetes / MODY gene, in which missense variants would be expected to increase T2D risk. Surprisingly, HNF4A Pro437Ser is associated with a halved risk of T2D and reduced risk of diabetes-related complications but increased non-HDL cholesterol. We additionally characterise a T2D risk-increasing variant which is common only in South and East Asian ancestral groups ( GP2 Val429Met), which is associated with lower BMI and phenotypic and genetic markers of insulin deficiency. We validate our findings through replication in independent multi-ancestry cohorts, in vitro functional assays, and integration of proteogenomic analysis. These findings highlight how the study of under-represented populations can identify biological mechanisms associated with disease phenotypes enriched in those populations.

10 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MBMargherita Bigossi
Margherita Bigossi
CMCyrielle Maroteau
Cyrielle Maroteau
ADAdem Y Dawed
Adem Y Dawed
ATAlasdair Taylor
Alasdair Taylor
SSSundararajan Srinivasan
Sundararajan Srinivasan
MSMoneeza K Siddiqui
Moneeza K Siddiqui
Background and Aims: The efficacy of statin therapy is hindered by adverse drug reactions, most frequently musculoskeletal symptoms. Variants in SLCO1B1 , which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentration of the drug and its metabolites. While pharmacogenetic testing of the loss-of-function Val174Ala (rs4149056T>C) is recommended to reduce risk of statin intolerance, current guidelines acknowledge the potential role of gain-of-function variants. This study tests the hypothesis that accounting for gain-of-function variants in SLCO1B1 , in addition to Val174Ala, will provide more reliable estimates of statin intolerance. Methods and Results: High-risk haplotypes were derived from Val174Ala and three common gain-of-function SLCO1B1 variants and compared to low-risk haplotypes. In statin users from Tayside Scotland, UK, those with high-risk haplotypes had increased odds across three phenotypes of statin intolerance (general statin intolerance: OR GSI 2.42[95%CI:1.29, 4.31], p=0.003; statin-related myopathy OR SRM 2.51[95%CI:1.28, 4.53],p=0.004; statin-related suspected rhabdomyolysis: OR SRSR 2.85[95%CI:1.03, 6.65],p=0.02). In contrast, using the Val174Ala genotype alone produced weaker results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (OR Val174Ala 1.99 [95%CI:1.01, 3.95],p=0.048; OR risk-haplotypes 1.76 [95%CI:1.16, 2.69],p=0.008). For those requiring high-dose statin therapy, high-risk haplotypes were more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared to Val174Ala (general statin intolerance: HR Val174Ala 2.49 [95%CI:1.09, 5.68],p=0.03; HR risk-haplotypes 2.44 [95%CI:1.46, 4.08],p<0.001). Exome-sequenced rare variants were found to be associated with the risk of intolerance (p=0.02). Conclusions: We demonstrate that accounting for gain-of-function variants in SLCO1B1 , in addition to Val174Ala, provides more reliable estimates of statin intolerance.